CD276 and cancer: 115 Lee et al. have investigated the role of B7-H3 in tumor immunity in mouse models. B7-H3-deficient animals or mice treated with an antagonistic antibody to B7-H3 showed decreased development of several malignancies-dependent NK and CD8+ T-cells. The suppression of B7-H3 stimulates the activity of cytotoxic lymphocytes in mice. Combining B7-H3 and PD-1 inhibitions improved the therapeutic control of advanced cancers. The B7-H3 checkpoint may thus serve as a potential target for cancer immunotherapy. 116